Literature DB >> 32718402

CureTB and continuity of care for globally mobile patients.

A Figueroa1, L Vonnahme2, K Burrell3, C Vera-García4, R K Gulati1.   

Abstract

BACKGROUND: In 2016, 3% of newly diagnosed patients with tuberculosis (TB) left the United States, of whom 24% moved to Mexico. Continuity of care for TB is important to ensure patients complete treatment and reduce TB transmission. CureTB provides continuity of care for patients with TB who move out of the United States by referring them for care at their destination.
METHODS: Analysis of CureTB data collected between January 2012 to December 2015 to describe demographics and outcomes of referred patients and examine factors contributing to successful treatment outcomes.
RESULTS: CureTB received 1347 referrals mostly from health departments and law enforcement agencies in the United States (92%). A total of 858 referrals were for patients with verified or possible TB (64%). Most patients moved to Mexico or other Latin American countries (96%) and completed treatment after departing (78%). Poor treatment outcomes were associated with being in custody (33%), not being interviewed by CureTB (30%), and not having diabetes (18%).
CONCLUSION: CureTB successfully promoted transnational continuity of care for patients by exchanging information with international public health authorities and linking them directly with patients. This patient-centered strategy helps improve TB treatment success and reduce the global burden and transmission of TB.

Entities:  

Mesh:

Year:  2020        PMID: 32718402      PMCID: PMC7720790          DOI: 10.5588/ijtld.19.0486

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

Review 1.  Tuberculosis, social determinants and co-morbidities (including HIV).

Authors:  R Duarte; K Lönnroth; C Carvalho; F Lima; A C C Carvalho; M Muñoz-Torrico; R Centis
Journal:  Pulmonology       Date:  2017-12-21

2.  Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis--a report from South India.

Authors:  Vijay Viswanathan; A Vigneswari; K Selvan; K Satyavani; R Rajeswari; Anil Kapur
Journal:  J Diabetes Complications       Date:  2013-12-24       Impact factor: 2.852

Review 3.  Patient adherence to tuberculosis treatment: a systematic review of qualitative research.

Authors:  Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink
Journal:  PLoS Med       Date:  2007-07-24       Impact factor: 11.069

4.  Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes.

Authors:  María Eugenia Jiménez-Corona; Luis Pablo Cruz-Hervert; Lourdes García-García; Leticia Ferreyra-Reyes; Guadalupe Delgado-Sánchez; Miriam Bobadilla-Del-Valle; Sergio Canizales-Quintero; Elizabeth Ferreira-Guerrero; Renata Báez-Saldaña; Norma Téllez-Vázquez; Rogelio Montero-Campos; Norma Mongua-Rodriguez; Rosa Areli Martínez-Gamboa; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  Thorax       Date:  2012-12-18       Impact factor: 9.102

5.  Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study.

Authors:  Mette Sagbakken; Jan C Frich; Gunnar Bjune
Journal:  BMC Public Health       Date:  2008-01-11       Impact factor: 3.295

6.  Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study.

Authors:  Weiguo Xu; Wei Lu; Yang Zhou; Limei Zhu; Hongbing Shen; Jianming Wang
Journal:  BMC Health Serv Res       Date:  2009-09-18       Impact factor: 2.655

7.  Use of Transnational Services to Prevent Treatment Interruption in Tuberculosis-Infected Persons Who Leave the United States.

Authors:  Cynthia A Tschampl; Deborah W Garnick; Edward Zuroweste; Moaven Razavi; Donald S Shepard
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.